Back to search results

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Abroad (travel likely)RecruitingPHASE2

Conditions

Intrahepatic Cholangiocarcinoma · FGFR2 Gene Rearrangement · FGFR2 Gene Mutation

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Alabama at Birmingham, Birmingham, Alabama, United States

    Contact: Study coordinator (Margaret (Meg) Thomas, MPH) · margaretannthomas@uabmc.edu · (205) 895-1802
    Contact: Principal Investigator (Mehmet Akce, MD)

  • Roswell Park Cancer Institute, Buffalo, New York, United States

    Contact: Study coordinator (Kayla Pham) · AskRoswell@RoswellPark.org · 1-800-767-9355
    Contact: Principal Investigator (Kannan Thanikachalam, MD)
Study leads

  • Mehmet Akce, MD

    Principal Investigator

    Sponsor-Investigator

View source on ClinicalTrials.gov(opens in a new tab)